Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
DDXSQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	49.2K 43.95K 40.97K 37.14K 69.9K 4.67M 70.44K 491K 192K 2.43M 185K 181K 7.79M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.73M 4.4M 3.99M 7.52M 502M 7.57M 52.77M 20.66M 261M 19.87M 19.43M 838M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
18-05-09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-31	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
16-07-28	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
16-07-19	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-06	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
16-06-13	Diadexus, Inc. Filed for Bankruptcy	CI
16-06-10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
16-05-23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
16-04-29	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ELI LILLY AND COMPANY	-1.36%	+0.78%	+42.36%	+91.48%	1,054B
JOHNSON & JOHNSON	-5.73%	-2.42%	+30.23%	+58.50%	636B
ABBVIE INC.	-2.40%	+2.88%	+19.13%	+85.43%	497B
MERCK & CO., INC.	-2.39%	+0.03%	+65.67%	+36.51%	359B
ROCHE HOLDING AG	-0.06%	+2.86%	+24.03%	+41.07%	345B
NOVARTIS AG	-0.55%	+1.81%	+14.16%	+36.31%	273B
ASTRAZENECA PLC	-1.08%	-0.52%	-6.51%	+8.40%	246B
AMGEN INC.	-1.13%	+2.54%	+41.19%	+45.32%	226B
GILEAD SCIENCES, INC.	-1.67%	+2.56%	+25.13%	+90.50%	187B
Average	-1.36%	+2.29%	+28.38%	+54.83%	382.22B
Weighted average by Cap.	-1.36%	+2.44%	+31.78%	+63.43%

	2014	2015
Net sales	26.11M 23.33M 21.74M 19.71M 37.1M 2.48B 37.39M 260M 102M 1.29B 98.07M 95.91M 4.14B	17.88M 15.98M 14.89M 13.5M 25.41M 1.7B 25.61M 178M 69.83M 883M 67.17M 65.69M 2.83B
Net income	-8.47M -7.56M -7.05M -6.39M -12.03M -804M -12.12M -84.45M -33.06M -418M -31.8M -31.1M -1.34B	-7.17M -6.4M -5.97M -5.41M -10.18M -680M -10.26M -71.48M -27.98M -354M -26.91M -26.32M -1.14B
Net Debt	-198K -177K -165K -149K -281K -18.79M -283K -1.97M -773K -9.77M -744K -727K -31.37M	5.24M 4.68M 4.36M 3.96M 7.45M 497M 7.5M 52.28M 20.46M 259M 19.68M 19.25M 830M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile